AMGN
Bearish signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Amgen Inc.
- Nom
- Amgen Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - General
- Bourse
- NASDAQ
- Capitalisation
- $241.8B
- Employés
- 31,500
- PDG
- Robert A. Bradway
- Site web
- https://www.amgen.com
- Marché
- ABBVAZNBMYGSKJNJLLY
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,481,692
Avg sell (VWAP, 90d window) $408.64 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-13 | Khosla Rachna | Sell · S | 1,252 | $416.43 | $521,365 | Form 4 |
| 2026-08-11 | Khosla Rachna | Sell · S | 2,000 | $412.57 | $825,134 | Form 4 |
| 2026-08-06 | Grygiel Nancy A. | Sell · S | 1,000 | $402.16 | $402,160 | Form 4 |
| 2026-08-06 | Miller Derek | Sell · S | 1,821 | $402.54 | $733,033 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-04 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-09-22 | David Taylor | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-22 | David Taylor | Purchase | $1,001 - $15,000 |
| 2026-08-26 | David Taylor | Sale | $1,001 - $15,000 |
| 2026-06-05 | David J. Taylor | Purchase | $1,001 - $15,000 |
| 2026-06-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-04-17 | Maria Elvira Salazar | Sale (Full) | $15,001 - $50,000 |
| 2026-03-24 | Maria Elvira Salazar | Purchase | $15,001 - $50,000 |
| 2026-02-26 | David J. Taylor | Sale (Full) | $1,001 - $15,000 |
| 2026-01-29 | David J. Taylor | Sale (Full) | $1,001 - $15,000 |
| 2026-01-16 | David J. Taylor | Purchase | $1,001 - $15,000 |
| 2025-12-03 | David J. Taylor | Sale (Full) | $1,001 - $15,000 |
| 2025-10-24 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-09-25 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-09-11 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-06-24 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-06-06 | Cliff Bentz | Purchase | $1,001 - $15,000 |
| 2025-05-14 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-05-05 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-04-16 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-04-16 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-04-11 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-04-08 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-02-24 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-02-11 | Dan Meuser | Sale (Full) | $1,001 - $15,000 |
| 2025-01-06 | Emily Randall | Sale (Full) | $1,001 - $15,000 |
| 2024-12-06 | Virginia Ann Foxx | Purchase | $1,001 - $15,000 |
| 2024-11-19 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2024-10-23 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-08-07 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2024-08-07 | Scott Franklin | Purchase | $50,001 - $100,000 |
| 2024-08-02 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2024-07-02 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2024-01-23 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2024-01-02 | Michael C. Burgess | Sale (Full) | $15,001 - $50,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-07-14 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-07-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-05 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-06-29 | Ro Khanna | Purchase | $50,001 - $100,000 |
| 2023-06-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-05-01 | Josh S. Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2023-04-28 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2023-04-12 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-04-05 | Michael C. Burgess | Purchase | $15,001 - $50,000 |
| 2023-03-27 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-03-24 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-03-14 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-03-06 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-02-22 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-10 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-01-27 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-01-09 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-12-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-09 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2022-10-19 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2022-10-12 | Kathy E. Manning | Sale (Full) | $1,001 - $15,000 |
| 2022-09-26 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2022-08-18 | Rick W. Allen | Purchase | $15,001 - $50,000 |
| 2022-08-03 | Kathy E. Manning | Sale (Full) | $1,001 - $15,000 |
| 2022-07-27 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2022-07-27 | Kathy E. Manning | Sale | $1,001 - $15,000 |
| 2022-07-27 | Kathy E. Manning | Sale | $1,001 - $15,000 |
| 2022-07-20 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2022-05-11 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-03-14 | Earl Blumenauer | Sale (Full) | $1,001 - $15,000 |
| 2022-03-03 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2022-02-24 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2022-02-22 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2022-02-17 | John Henry Rutherford | Sale (Full) | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-02-11 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2021-07-19 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2021-04-30 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2021-03-04 | Carol Devine Miller | Purchase | $15,001 - $50,000 |
| 2021-02-16 | Peter Meijer | Sale (Full) | $1,001 - $15,000 |
| 2021-02-05 | Kurt Schrader | Purchase | $1,001 - $15,000 |
| 2021-01-15 | Kathy E. Manning | Sale (Partial) | $1,001 - $15,000 |
| 2021-01-15 | Kathy E. Manning | Sale (Partial) | $1,001 - $15,000 |
| 2020-10-22 | Josh S. Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2020-10-08 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-07-28 | Carol Devine Miller | Purchase | $15,001 - $50,000 |
| 2020-05-29 | John Yarmuth | Purchase | $1,001 - $15,000 |
| 2020-05-29 | John Yarmuth | Sale (Partial) | $1,001 - $15,000 |
| 2020-05-15 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-05-01 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2020-02-20 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2020-01-14 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-01-09 | Michael Gallagher | Sale (Full) | $1,001 - $15,000 |
| 2019-11-07 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2019-09-27 | Rick W. Allen | Purchase | $15,001 - $50,000 |
| 2019-08-29 | Rick W. Allen | Purchase | $15,001 - $50,000 |
Signal
Bearish signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
AMGN shows solid operational fundamentals with improving margins and deleveraging progress, but the weak catalyst score (35) driven by mixed congressional trading signals — buys offset by sells — fails to provide a…
The first sentence of the analysis written for AMGN on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.14 · operating margin 29%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 70.8% | 61.5% | 70.1% | 75.7% | 75.2% | |
| Ebit Margin | 31.9% | 23.2% | 38.1% | 33.2% | 30.4% | |
| Ebitda Margin | 46.0% | 40.0% | 52.5% | 46.2% | 43.5% | |
| Operating Profit Margin | 29.1% | 21.7% | 28.0% | 36.3% | 29.4% | |
| Pretax Profit Margin | 24.4% | 13.8% | 27.9% | 27.9% | 25.8% | |
| Continuous Operations Profit Margin | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% | |
| Net Profit Margin | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% | |
| Bottom Line Profit Margin | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% | |
| Current Ratio | 1.140 | 1.257 | 1.649 | 1.414 | 1.591 | |
| Quick Ratio | 0.896 | 0.954 | 1.132 | 1.100 | 1.256 | |
| Solvency Ratio | 0.157 | 0.113 | 0.119 | 0.162 | 0.171 | |
| Cash Ratio | 0.358 | 0.518 | 0.595 | 0.486 | 0.656 | |
| Price To Earnings Ratio | 22.841 | 34.205 | 22.932 | 21.563 | 21.757 | |
| Price To Earnings Growth Ratio | 0.259 | -0.870 | 7.350 | 1.212 | -1.310 | |
| Forward Price To Earnings Growth Ratio | 0.259 | -0.870 | 7.350 | 1.212 | -1.310 | |
| Price To Earnings Diluted Ratio | 23.001 | 34.476 | 23.060 | 21.688 | 21.884 | |
| Price To Earnings Diluted Growth Ratio | 0.261 | -0.873 | 7.349 | 1.218 | -1.327 | |
| Price To Book Ratio | 20.339 | 23.993 | 24.726 | 38.596 | 19.139 | |
| Price To Sales Ratio | 4.793 | 4.219 | 5.466 | 5.368 | 4.936 | |
| Price To Free Cash Flow Ratio | 21.740 | 13.566 | 20.939 | 16.084 | 15.300 | |
| Price To Operating Cash Flow Ratio | 17.684 | 12.272 | 18.190 | 14.536 | 13.847 | |
| Debt To Assets Ratio | 0.603 | 0.654 | 0.665 | 0.598 | 0.545 | |
| Debt To Equity Ratio | 6.307 | 10.226 | 10.368 | 10.638 | 4.971 | |
| Debt To Capital Ratio | 0.863 | 0.911 | 0.912 | 0.914 | 0.833 | |
| Long Term Debt To Capital Ratio | 0.852 | 0.906 | 0.910 | 0.911 | 0.832 | |
| Financial Leverage Ratio | 10.463 | 15.627 | 15.590 | 17.788 | 9.129 | |
| Working Capital Turnover Ratio | 7.736 | 3.741 | 3.058 | 3.843 | 3.113 | |
| Operating Cash Flow Ratio | 0.391 | 0.497 | 0.461 | 0.620 | 0.760 | |
| Operating Cash Flow Sales Ratio | 0.271 | 0.344 | 0.300 | 0.369 | 0.356 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.813 | 0.905 | 0.869 | 0.904 | 0.905 | |
| Debt Service Coverage Ratio | 2.126 | 1.915 | 3.164 | 3.795 | 8.168 | |
| Interest Coverage Ratio | 3.875 | 2.300 | 2.747 | 6.804 | 6.382 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.165 | 3.237 | 5.870 | 6.110 | 106.448 | |
| Operating Cash Flow Coverage Ratio | 0.182 | 0.191 | 0.131 | 0.250 | 0.278 | |
| Capital Expenditure Coverage Ratio | 5.360 | 10.484 | 7.618 | 10.386 | 10.524 | |
| Dividend Paid And Capex Coverage Ratio | 1.426 | 1.938 | 1.495 | 1.894 | 1.893 | |
| Dividend Payout Ratio | 0.665 | 1.181 | 0.678 | 0.640 | 0.681 | |
| Enterprise Value Multiple | 13.112 | 14.161 | 14.037 | 14.185 | 13.594 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 70.8% | ▲9.3% | ▲0.1% |
| Ebit Margin | 31.9% | ▲8.7% | ▲0.5% |
| Ebitda Margin | 46.0% | ▲6.0% | ▲0.4% |
| Operating Profit Margin | 29.1% | ▲7.3% | ▲0.1% |
| Pretax Profit Margin | 24.4% | ▲10.6% | ▲0.5% |
| Continuous Operations Profit Margin | 21.0% | ▲8.8% | ▲0.1% |
| Net Profit Margin | 21.0% | ▲8.8% | ▲0.1% |
| Bottom Line Profit Margin | 21.0% | ▲8.8% | ▲0.1% |
| Current Ratio | 1.140 | ▼-0.117 | ▼-0.270 |
| Quick Ratio | 0.896 | ▼-0.058 | ▼-0.172 |
| Solvency Ratio | 0.157 | ▲0.045 | ▲0.013 |
| Cash Ratio | 0.358 | ▼-0.160 | ▼-0.165 |
| Price To Earnings Ratio | 22.841 | ▼-11.364 | ▼-1.819 |
| Price To Earnings Growth Ratio | 0.259 | ▲1.129 | ▼-1.069 |
| Forward Price To Earnings Growth Ratio | 0.259 | ▲1.129 | ▼-1.069 |
| Price To Earnings Diluted Ratio | 23.001 | ▼-11.475 | ▼-1.821 |
| Price To Earnings Diluted Growth Ratio | 0.261 | ▲1.134 | ▼-1.065 |
| Price To Book Ratio | 20.339 | ▼-3.654 | ▼-5.020 |
| Price To Sales Ratio | 4.793 | ▲0.574 | ▼-0.164 |
| Price To Free Cash Flow Ratio | 21.740 | ▲8.174 | ▲4.214 |
| Price To Operating Cash Flow Ratio | 17.683 | ▲5.412 | ▲2.378 |
| Debt To Assets Ratio | 0.603 | ▼-0.052 | ▼-0.010 |
| Debt To Equity Ratio | 6.307 | ▼-3.919 | ▼-2.195 |
| Debt To Capital Ratio | 0.863 | ▼-0.048 | ▼-0.023 |
| Long Term Debt To Capital Ratio | 0.852 | ▼-0.053 | ▼-0.030 |
| Financial Leverage Ratio | 10.463 | ▼-5.164 | ▼-3.256 |
| Working Capital Turnover Ratio | 7.736 | ▲3.995 | ▲3.438 |
| Operating Cash Flow Ratio | 0.391 | ▼-0.107 | ▼-0.155 |
| Operating Cash Flow Sales Ratio | 0.271 | ▼-0.073 | ▼-0.057 |
| Free Cash Flow Operating Cash Flow Ratio | 0.813 | ▼-0.091 | ▼-0.066 |
| Debt Service Coverage Ratio | 2.126 | ▲0.211 | ▼-1.708 |
| Interest Coverage Ratio | 3.875 | ▲1.575 | ▼-0.546 |
| Short Term Operating Cash Flow Coverage Ratio | 2.165 | ▼-1.071 | ▼-22.601 |
| Operating Cash Flow Coverage Ratio | 0.182 | ▼-0.009 | ▼-0.024 |
| Capital Expenditure Coverage Ratio | 5.359 | ▼-5.124 | ▼-3.515 |
| Dividend Paid And Capex Coverage Ratio | 1.426 | ▼-0.512 | ▼-0.303 |
| Dividend Payout Ratio | 0.664 | ▼-0.517 | ▼-0.105 |
| Enterprise Value Multiple | 13.112 | ▼-1.049 | ▼-0.706 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $176.09B | $141.01B | $154.09B | $141.30B | $128.23B | |
| Enterprise value | $221.57B | $189.13B | $207.76B | $172.62B | $153.55B | |
| EV / Sales | 6.03x | 5.66x | 7.37x | 6.56x | 5.91x | |
| EV / Op. cash flow | 22.25x | 16.46x | 24.53x | 17.76x | 16.58x | |
| EV / Free cash flow | 27.35x | 18.20x | 28.23x | 19.65x | 18.32x | |
| EV / EBITDA | 13.11x | 14.16x | 14.04x | 14.19x | 13.59x | |
| Net debt / EBITDA | 2.69x | 3.60x | 3.63x | 2.57x | 2.24x | |
| Current ratio | 1.14x | 1.26x | 1.65x | 1.41x | 1.59x | |
| Income quality | 1.29x | 2.81x | 1.26x | 1.48x | 1.57x | |
| Graham number | $72 | $43 | $57 | $43 | $52 | |
| Graham net-net | -$116 | -$120 | -$129 | -$83 | -$70 | |
| Tax burden | 85.9% | 88.7% | 85.5% | 89.2% | 87.9% | |
| Interest burden | 76.5% | 59.4% | 73.2% | 83.9% | 84.8% | |
| Working capital | $3.57B | $5.93B | $11.94B | $6.50B | $7.20B | |
| Invested capital | $53.04B | $58.81B | $69.15B | $43.53B | $42.46B | |
| Return on assets | 8.5% | 4.5% | 6.9% | 10.1% | 9.6% | |
| Operating ROA | 11.7% | 7.7% | 9.7% | 15.1% | 12.3% | |
| Return on tangible assets | 15.5% | 9.0% | 14.6% | 19.6% | 19.0% | |
| Return on equity | 89.1% | 69.6% | 107.8% | 179.0% | 88.0% | |
| Return on invested capital | 13.2% | 8.9% | 8.4% | 16.7% | 13.7% | |
| Return on capital employed | 16.4% | 10.6% | 10.0% | 19.4% | 15.6% | |
| Earnings yield | 4.4% | 2.9% | 4.4% | 4.6% | 4.6% | |
| Free cash flow yield | 4.6% | 7.4% | 4.8% | 6.2% | 6.5% | |
| Capex / Op. cash flow | 18.7% | 9.5% | 13.1% | 9.6% | 9.5% | |
| Capex / Depreciation | 36.0% | 19.6% | 27.3% | 27.4% | 25.9% | |
| Capex / Sales | 5.1% | 3.3% | 3.9% | 3.6% | 3.4% | |
| SG&A / Sales | 19.2% | 21.2% | 21.9% | 20.6% | 20.7% | |
| R&D / Sales | 19.0% | 17.8% | 17.0% | 16.8% | 24.3% | |
| Stock comp / Sales | 1.3% | 1.6% | 1.5% | 1.5% | 1.3% | |
| Intangibles / Total assets | 45.2% | 50.5% | 52.8% | 48.5% | 49.2% | |
| Days sales outstanding | 95d | 82d | 103d | 89d | 82d | |
| Days payables outstanding | 81d | 54d | 69d | 90d | 77d | |
| Operating cycle | 307d | 281d | 516d | 370d | 313d | |
| Cash conversion cycle | 226d | 226d | 447d | 280d | 236d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-06 Amgen Inc. $AMGN Shares Purchased by MassMutual Private Wealth & Trust FSB MassMutual Private Wealth and Trust FSB raised its position in Amgen Inc. (NASDAQ: AMGN) by 105.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,514 shares of the medical research company''s stock after purchasing an additional 6,947 shares during
- 2026-10-05 Amgen Inc. $AMGN Shares Purchased by Ferguson Wellman Capital Management Inc. Ferguson Wellman Capital Management Inc. boosted its holdings in Amgen Inc. (NASDAQ: AMGN) by 4.8% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 259,022 shares of the medical research company''s stock after acquiring an additional 11,950 shares during
- 2026-10-05 2,546 Amgen Inc. $AMGN Shares Sold by Argent Capital Management LLC Argent Capital Management LLC lowered its position in shares of Amgen Inc. (NASDAQ: AMGN) by 3.5% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 69,486 shares of the medical research company''s stock after selling 2,546 shares during the quarter. Amgen comprises 0.2% of Argent
- 2026-10-04 Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? Amgen offers a diversified portfolio of established therapies across oncology and inflammation supported by robust cash flow. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market and is expanding into high-growth gene therapies.
- 2026-10-01 Amgen (AMGN) Stock Dips While Market Gains: Key Facts Amgen (AMGN) closed at $407.27 in the latest trading session, marking a -3.38% move from the prior day.
- 2026-10-01 Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
- 2026-09-29 Amgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells Investors On September 29, 2026, Amgen Inc (AMGN) shares rose 1.3% to a current price of $423.64, within a 52-week range of $274.02 to $447.03. This price movement reflec
- 2026-09-29 Why Amgen''s 6% Dividend Raise Masks a Tougher Road Ahead Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
- 2026-09-28 Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus Microsoft, Bloom Energy and Amgen highlight Zacks'' latest market moves, with strong gains across Focus List, recommendation and dividend portfolios.
- 2026-09-28 Should You Buy QQQ or VUG Right Now? Here''s What History Suggests. It all comes down to portfolio construction -- one is logical, one isn''t.